Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

BIOMARKER:

EGFR G719X

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

Related biomarkers:

‹

›

Related tests:

therascreen® EGFR RGQ PCR Kit (5)

therascreen® EGFR RGQ PCR Kit (5)

EGFR G719X	Non Small Cell Lung Cancer	EGFR G719X	Non Small Cell Lung Cancer	osimertinib Sensitive: A2 - Guideline osimertinib Sensitive : A2	osimertinib Sensitive: A2 - Guideline osimertinib Sensitive : A2
EGFR G719X	Non Small Cell Lung Cancer	EGFR G719X	Non Small Cell Lung Cancer	afatinib Sensitive: A2 - Guideline afatinib Sensitive : A2	afatinib Sensitive: A2 - Guideline afatinib Sensitive : A2
EGFR G719X	Non Small Cell Lung Cancer	EGFR G719X	Non Small Cell Lung Cancer	erlotinib Sensitive: A2 - Guideline erlotinib Sensitive : A2	erlotinib Sensitive: A2 - Guideline erlotinib Sensitive : A2
EGFR G719X	Non Small Cell Lung Cancer	EGFR G719X	Non Small Cell Lung Cancer	gefitinib Sensitive: A2 - Guideline gefitinib Sensitive : A2	gefitinib Sensitive: A2 - Guideline gefitinib Sensitive : A2
EGFR G719X	Non Small Cell Lung Cancer	EGFR G719X	Non Small Cell Lung Cancer	dacomitinib Sensitive: A2 - Guideline dacomitinib Sensitive : A2	dacomitinib Sensitive: A2 - Guideline dacomitinib Sensitive : A2
EGFR G719X	Non Small Cell Lung Cancer	EGFR G719X	Non Small Cell Lung Cancer	neratinib Sensitive: C2 – Inclusion Criteria neratinib Sensitive : C2	neratinib Sensitive: C2 – Inclusion Criteria neratinib Sensitive : C2
EGFR G719X	Non Small Cell Lung Cancer	EGFR G719X	Non Small Cell Lung Cancer	SZMD4 Sensitive: C2 – Inclusion Criteria SZMD4 Sensitive : C2	SZMD4 Sensitive: C2 – Inclusion Criteria SZMD4 Sensitive : C2
EGFR G719X	Non Small Cell Lung Cancer	EGFR G719X	Non Small Cell Lung Cancer	MET306 Sensitive: C2 – Inclusion Criteria MET306 Sensitive : C2	MET306 Sensitive: C2 – Inclusion Criteria MET306 Sensitive : C2
EGFR G719X	Non Small Cell Lung Cancer	EGFR G719X	Non Small Cell Lung Cancer	lazertinib Sensitive: C2 – Inclusion Criteria lazertinib Sensitive : C2	lazertinib Sensitive: C2 – Inclusion Criteria lazertinib Sensitive : C2
EGFR G719X	Lung Adenocarcinoma	EGFR G719X	Lung Adenocarcinoma	afatinib Sensitive: C3 – Early Trials afatinib Sensitive : C3	afatinib Sensitive: C3 – Early Trials afatinib Sensitive : C3
EGFR G719X	Non Small Cell Lung Cancer	EGFR G719X	Non Small Cell Lung Cancer	EGFR inhibitor Sensitive: C3 – Early Trials EGFR inhibitor Sensitive : C3	EGFR inhibitor Sensitive: C3 – Early Trials EGFR inhibitor Sensitive : C3
EGFR G719X	Non Small Cell Lung Cancer	EGFR G719X	Non Small Cell Lung Cancer	Tyrosine kinase inhibitor Resistant: C3 – Early Trials Tyrosine kinase inhibitor Resistant : C3	Tyrosine kinase inhibitor Resistant: C3 – Early Trials Tyrosine kinase inhibitor Resistant : C3
EGFR G719X	Lung Cancer	EGFR G719X	Lung Cancer	pan-HER inhibitor Sensitive: D – Preclinical pan-HER inhibitor Sensitive : D	pan-HER inhibitor Sensitive: D – Preclinical pan-HER inhibitor Sensitive : D